Literature DB >> 15517124

[Therapy of inflammatory kidney diseases. More than steroids?].

J Galle1, S Seibold.   

Abstract

The term "inflammatory kidney diseases" characterizes primarily immunopathogenetically driven diseases, affecting both kidneys. Bacterial infections, or primarily interstitial nephritis, shall not be considered in this overview. Classification and terminology of inflammatory kidney diseases follow morphological criteria, acuteness of the clinical course, and concomitant organ affection. The clinical course and pathology of inflammatory kidney diseases have been reviewed extensively in this journal in 1997 and 2002.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15517124     DOI： 10.1007/s00108-004-1298-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  20 in total

1.  Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

Authors:  U Specks; F C Fervenza; T J McDonald; M C Hogan
Journal:  Arthritis Rheum       Date:  2001-12

2.  [Glomerulonephritis].

Authors:  U Schmidt; J Franke; U Thomae; J Mann
Journal:  Internist (Berl)       Date:  2002-06       Impact factor: 0.743

Review 3.  [Immunosuppression in therapy of glomerulonephritis].

Authors:  B Grabensee; D Bach; P Heering
Journal:  Internist (Berl)       Date:  1997-06       Impact factor: 0.743

4.  The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.

Authors:  J V Donadio; J P Grande; E J Bergstralh; R A Dart; T S Larson; D C Spencer
Journal:  J Am Soc Nephrol       Date:  1999-08       Impact factor: 10.121

5.  Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.

Authors:  R Nowack; U Göbel; P Klooker; O Hergesell; K Andrassy; F J van der Woude
Journal:  J Am Soc Nephrol       Date:  1999-09       Impact factor: 10.121

6.  Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients.

Authors:  Wilhelm H Schmitt; E Christiaan Hagen; Irmgard Neumann; Rainer Nowack; Luis Felipe Flores-Suárez; Fokko J van der Woude
Journal:  Kidney Int       Date:  2004-04       Impact factor: 10.612

7.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

8.  Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  Anthony Booth; Lorraine Harper; Tariq Hammad; Paul Bacon; Megan Griffith; Jeremy Levy; Caroline Savage; Charles Pusey; David Jayne
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

9.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

10.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study.

Authors:  Piero Ruggenenti; Carlos Chiurchiu; Varusca Brusegan; Mauro Abbate; Annalisa Perna; Claudia Filippi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.